Stevanato Group S.p.A.

NYSE:STVN

Medical - Instruments & Supplies

Healthcare
$15.36 +3.90%

+$0.67 today

Market cap
$4.20B
Beta
0.78
P/E (TTM)
29.9
EPS (TTM)
$0.52
Dividend yield
0.35%
52W Low $12.89High $28.00

Volume 0.61M

Average 0.52M

STVN Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Stevanato Group S.p.A.NYSE: STVN

Total Equity · Q2 FY2026 · quarter ended Jun 2026

Total equity rises 10.9% from a year ago

Total equity stood at €1.55B at the end of Q2 FY2026, up 10.9% from a year earlier and up 1.2% from the prior quarter. Over 3 fiscal years it compounded at +14.3% a year.

Context

  • Total equity amounted to 59.2% of total assets at the end of Q2 FY2026, down 0.3 pp from a year earlier.
  • Total equity increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +10.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
€1.55B+1.2% QoQ
Last fiscal yearDec 2025
€1.49B+5.8% YoY
Year agoJun 2025
€1.4B+10.9% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.9%——
1 year+5.8%——
3-year CAGR+14.3%——
5-year CAGR——
10-year CAGR——

Total Equity history

EUR · from the balance sheet

Latest · FY2025
1.49B EUR
Year-over-year change
+5.8%
4-year CAGR
+15.3%

Total Equity vs competitors

How STVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +10.9% is the 5th highest of 11, against a peer median of -1.3%.
  • Total equity amounts to 59.2% of total assets for STVN, versus a peer median of 48.0%.
STVN Competitors
Total Equity for STVN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BLCOBausch + Lomb CorporationJun 2026$6.44B USD-1.0%-2.8%46.5%
AVTRAvantor, Inc.Jun 2026$5.63B USD-10.4%+4.7%48.6%
TFXTeleflex IncorporatedJun 2026$2.9B USD-31.5%-8.1%42.8%
ATRAptarGroup, Inc.Jun 2026$2.67B USD-1.6%+9.5%52.1%
BTSGBrightSpring Health Services, Inc. Common StockSep 2026$2.19B USD+20.0%+34.0%34.9%
MMSIMerit Medical Systems, Inc.Sep 2026$1.74B USD+14.1%+11.5%—
STVNStevanato Group S.p.A.Jun 2026€1.55B EUR+10.9%+14.3%59.2%
NUVLNuvalent, Inc.Mar 2026$1.17B USD+16.2%+39.2%88.2%
CHEChemed CorporationJun 2026$830.51M USD-30.7%+7.0%52.6%
MASIMasimo CorporationApr 2026$788.9M USD-16.6%-18.6%48.0%
AXSMAxsome Therapeutics, Inc.Jun 2026$83.3M USD+14.0%-6.9%10.9%
Peer median (excluding STVN) —-1.3%+5.8%48.0%

Competitors are the stored peer set for STVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents411.04M228.74M69.6M98.27M130.54M
Short-term Investments27.17M27.91M749K02.2M
Net Receivables278.42M369.48M522.48M529.87M542.17M
Inventory148.92M213.25M255.32M245.22M268.09M
Other Current Assets49K5.69M3.63M933K(8.6M)
Total Current Assets865.97M845.78M861.89M880.12M934.4M
Property, Plant & Equipment (Net)415.41M660.69M1.05B1.26B1.4B
Goodwill47.24M47.24M49.98M49.98M49.96M
Intangible Assets31.93M32.16M30.99M33.59M36.85M
Long-term Investments1.97M1.83M5.15M5.64M6M
Tax Assets55.88M69.21M76.25M95.34M103.86M
Other Non-current Assets447K2.8M577K08.6M
Total Non-current Assets552.87M813.92M1.21B1.45B1.61B
Total Assets1.42B1.66B2.07B2.33B2.54B
Account Payables164.79M239.18M277.82M231.02M263.19M
Short-term Debt37.17M64.63M135.6M106.84M121.69M
Tax Payables27.82M42.09M30.82M32.06M0
Deferred Revenue50.61M53.89M58.8M44.67M43.78M
Other Current Liabilities5.33M(3.73M)11.15M15.45M106.91M
Total Current Liabilities338.62M462.5M574.39M477.47M535.57M
Long-term Debt183.99M133.75M242.05M305.23M337.64M
Deferred Tax Liabilities19.11M20.95M9.62M12.56M13.29M
Deferred Revenue (Non-current)0039.42M44.05M98.76M
Other Non-current Liabilities17.9M31.93M60.35M73.32M62.07M
Total Non-current Liabilities238.56M201.29M364.54M446.96M521.38M
Total Liabilities577.18M663.79M938.93M924.43M1.06B
Common Stock21.7M21.7M21.7M22.23M22.22M
Retained Earnings0623.35M757.86M863.44M876.41M
Accumulated OCI686.06M(10.49M)(9.11M)(13.75M)54.95M
Other Stockholders Equity134.32M0000
Minority Interest(415K)(220K)115K46K37.98K
Total Equity841.66M995.91M1.13B1.4B1.49B
Total Debt244.29M218.37M396.59M428.97M470.7M
Net Debt(166.75M)(10.37M)326.99M330.7M340.16M

Stevanato Group S.p.A.

NYSE:STVN

Intrinsic Alpha fair value

Locked

Current Price

$15.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.